RNA sequencing (RNAseq) services for gene expression profiling, transcriptomic analysis, biomarker discovery and precision medicine research.
Use RNAseq to identify differentially expressed genes, signaling pathways, fusions, and immune signatures in a single workflow.
With access to leading platforms in next-generation sequencing (NGS) and spatial biology, CellCarta’s comprehensive services include sample preparation and multi-modal analysis.
Validated in a GCLP and CAP/CLIA-accredited environment, our RNAseq services can be readily implemented for biomarker discovery and clinical trials.
Our RNAseq workflows are designed to meet your study’s needs. Our offerings span end-to-end, including RNA extraction, library preparation, sequencing, and final reporting.
Our workflows use the latest technologies for quality, high-throughput RNAseq, including NovaSeq X Plus, NovaSeq 6000, NextSeq 550Dx.
Our RNAseq services are validated for use with a wide range of clinical sample types, including fresh or fixed tissue, whole blood, and biofluids.
CellCarta has validated several OTS RNAseq assays for clinical implementation, including:
Alternatively, we can develop and validate a custom gene expression panel and assay for any gene or gene set, providing coverage for a broad range of biological pathways and disease states.
Our expert BioIT team can support your study through standard analysis of bulk RNAseq data, including:
Furthermore, our advanced analysis pipeline can perform variant calling, immune deconvolution, HLA typing, and calculates expressed tumor mutational burden (eTMB) and MSI from a single bulk RNAseq dataset.
Our RNAseq workflows are designed to meet your study’s needs. Our offerings span end-to-end, including RNA extraction, library preparation, sequencing, and final reporting.
Our workflows use the latest technologies for quality, high-throughput RNAseq, including NovaSeq X Plus, NovaSeq 6000, NextSeq 550Dx.
Our RNAseq services are validated for use with a wide range of clinical sample types, including fresh or fixed tissue, whole blood, and biofluids.
CellCarta has validated several OTS RNAseq assays for clinical implementation, including:
Alternatively, we can develop and validate a custom gene expression panel and assay for any gene or gene set, providing coverage for a broad range of biological pathways and disease states.
Our expert BioIT team can support your study through standard analysis of bulk RNAseq data, including:
Furthermore, our advanced analysis pipeline can perform variant calling, immune deconvolution, HLA typing, and calculates expressed tumor mutational burden (eTMB) and MSI from a single bulk RNAseq dataset.
CellCarta collaborated with Watchmaker to validate the RNA Library Prep with Polaris Depletion for whole transcriptome sequencing in challenging sample types. This workflow is shown to be a suitable alternative to exome-capture based RNAseq workflows, with several possible clinical applications.
Enable large-scale transcriptomic analysis of individual cells by implementing CellCarta’s single-cell sequencing services into your research. Single-cell sequencing unveils in-depth information from complex biological samples, making it a powerful tool for therapeutic development.
CellCarta developed the RNA-Seq Bio-IT model that extracts information on eTMB, MSI, tumor infiltrating lymphocytes (TILs), and immune gene signatures using only RNAseq data. This model accurately predicts patient response to immune checkpoint inhibition therapy without using a multiomics approach.
Dependable RNAseq services that deliver precision, accuracy, and sensivity.
Cutting-edge Technology
Integrated Bioanalysis Pipeline
Global Execution
Customized Workflows
Scalable Solutions
Nucleic acid quantification with superior accuracy, precision, and sensitivity.
Support for qPCR applications using off-the-shelf assays or custom, validated primers.
Precise, high-throughput analysis of genetic material with both speed and scalability.
CellCarta's RNA sequencing services cover the complete experimental spectrum: RNA extraction, library preparation, sequencing, bioinformatics analysis, and reporting.
Sequencing is performed on leading NGS platforms including the NovaSeq X Plus, NovaSeq 6000, and NextSeq 550Dx. Complementary platforms such as NanoString nCounter and GeoMx Digital Spatial Profiler extend the offering into spatial biology. Every project is supported by expert data analysis and a structured report.
Yes. CellCarta has developed a workflow to predict immune checkpoint inhibition response using only RNA-seq data.
Tumor RNA profiles can be used to assess expressed tumor mutational burden (eTMB), microsatellite instability (MSI), tumor-infiltrating lymphocytes (TILs), and immune gene signatures — providing actionable biomarker insights without an intensive multi-omic approach. Learn more here.
CellCarta accepts a wide variety of sample types, including fresh tissue, fresh frozen tissue, fixed tissue, body fluids, whole blood, and isolated cells. Depletion of unwanted RNA molecules from total RNA is also offered, supporting cleaner signal from complex or low-input samples.
Yes. Single-cell RNA sequencing is available through the 10x Genomics Chromium platform, enabling high-resolution transcriptomic profiling at the individual cell level.
For spatial context, CellCarta offers spatial transcriptomics via 10x Genomics Visium and NanoString GeoMx Digital Spatial Profiler (DSP), overlaying gene expression data with tissue architecture. Learn more about our single-cell RNA sequencing services here.
